A Retrospective Analysis of Spinal Anaesthesia for TURBT Procedures in Elderly Patients
A Retrospective Analysis of Spinal Anaesthesia for Transurethral Resection of Bladder Tumour in Elderly Patients: A Single Centre Experience From 2007 to 2017
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Karolina Dobronska, MD, PhD
- Phone Number: 48 501 323 534
- Email: karolinadobronska@gmail.com
Study Contact Backup
- Name: Lidia I Jureczko, MD, PhD
- Phone Number: 48 501 054 419
- Email: jureczko@gmail.com
Study Locations
-
-
-
Warsaw, Poland, 02-005
- Recruiting
- I Department of Anaesthesiology and Intensive Care, Medical University of Warsaw
-
Contact:
- Karolina Dobronska, MD
- Phone Number: +48 22 501 17 27
- Email: karolinapladzyk@gmail.com
-
Contact:
- Lidia I Jureczko, PhD MD
- Phone Number: +48 22 501 17 27
- Email: jureczko@gmail.com
-
Principal Investigator:
- Karolina Dobronska, MD
-
Sub-Investigator:
- Lidia I Jureczko, PhD MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- TURBT procedure
- spinal anaesthesia
- age over 60
Exclusion Criteria:
- general anaesthesia
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effectiveness of spinal anaesthesia for TURBT evaluated by a number of participants that had the procedure done, without the need of conversion to general anaesthesia .
Time Frame: 6 months
|
The investigator evaluates whether the procedure could be completely performed under spinal anesthesia
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The influence of the bupivacaine spinal dose on bradycardia evaluated by a heart rate measurements
Time Frame: 6 months
|
The investigator evaluates the bupivacaine doses, heart rate and the need to give atropine
|
6 months
|
|
The influence of the bupivacaine dose on hypotension evaluated by the non-invasive blood pressure measurements
Time Frame: 6 months
|
The investigator evaluates the bupivacaine doses, blood pressure and the need to give ephedrine
|
6 months
|
|
Experienced and non-experienced anesthetist does it influence the bupivacaine dose
Time Frame: 6 months
|
The investigator evaluates the doses of bupivacaine spinal given by specialist, young and advanced trainee.
|
6 months
|
|
Experienced and non-experienced anesthetist does it influence the spinal anaesthesia success
Time Frame: 6 months
|
The investigator evaluates the success rate of spinal anaesthesia given by specialist, young and advanced trainee.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- U/2/2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Tumor
-
NCT01826565UnknownProstate Cancer | Bladder Cancer | Bladder Tumor | Prostate Tumor
-
NCT03518320TerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor (T) T3B | Bladder Cancer TNM Staging Regional Lymph Node (N) N0 | Bladder Cancer TNM Staging Regional Lymph Node (N) N1 | Bladder Cancer TNM Staging Distant Metastasis (M) M0
-
NCT01920269CompletedBladder Cancer TNM Staging Primary Tumor (T) Ta | Bladder Cancer TNM Staging Primary Tumor (T) T1 | Bladder Cancer Transitional Cell Grade
-
NCT04200963CompletedNeoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma
-
NCT04310813Completed
-
NCT03331705Unknown
-
NCT01581723UnknownUrinary Bladder Tumor
-
NCT03839472WithdrawnNon-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)
-
NCT03517995WithdrawnBladder Cancer | Urothelial Carcinoma | Bladder Tumor